CPIX and RDHL Related Headlines
Go Back- RedHill initiates enforcement of $10.9 million judgment in Korea
- RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
- RedHill explores opaganib for ebola outbreak response
- RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
- RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests
- RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
- H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
- Joint U.S. Commercialization of RedHill's Talicia® Commences
- Cumberland Pharmaceuticals partners with RedHill for Talicia commercialization
- CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
- Cumberland Pharmaceuticals invests $4 million in RedHill's Talicia business
- RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
CPIX and RDHL Related Press Releases
Go Back- RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
- RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
- RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
- H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
- Joint U.S. Commercialization of RedHill's Talicia® Commences
- CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
- RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
